

Special Issue

Personalized Oncology in Gastrointestinal Cancer: Emerging Therapies and Challenges

Message from the Guest Editor

This Special Issue will mainly focus on analyzing present and future approaches for the treatment of gastrointestinal (GI) cancer patients, with a glimpse into novel perspectives and future challenges in clinical practice. GI cancers are one of the most common worldwide cause of cancer-related death. They include a wide spectrum of neoplasms, including esophageal, gastric, hepatic, biliary, pancreatic, small bowel and large bowel as well as rectal cancers. In the last decade, significant improvements have been made in the prognosis of patients affected by these tumors thanks to the development of new treatments, which include cytotoxic drugs, targeted therapies, and immunotherapy. Recently, emerging and novel biomarkers have been identified and validated with a huge impact on patients' outcomes and improving the treatment landscape. Despite these advances, GI cancers still represent a major public health problem worldwide; hence, it is mandatory to develop novel therapeutic approaches. We cordially invite experts in the field to submit original research or review articles to better understand and explore this important topic.

Guest Editor

Dr. Carmelo Laface
Medical Oncology, AO "S. Croce and Carle", Cuneo, Italy

Deadline for manuscript submissions

20 April 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/245234

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://jpm.mdpi.com)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).